Cadrenal Therapeutics, Inc. announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin, intended for pediatric patients with Kawasaki disease who develop coronary artery aneurysms. The company is following a dual-track portfolio strategy involving the Global Pharma Track for CAD-1005 and the Regional & Rare Disease Track for tecarfarin. Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic solutions for rare and regional diseases.
